When a medication is proven to be associated with risks, the Food and Drug Administration (FDA) or drug manufacturer communicates with healthcare providers across the country via Dear Health Care Provider (DHCP) letters, also known as Dear Doctor letters, intended to alert physicians and other health care providers about important new or updated information regarding a human drug or biologic.
On July 26, 2016, the FDA issued a press release stating that they approved safety labeling changes for fluoroquinolones, to enhance warnings about their association with disabling and potentially permanent adverse events and to limit their use in patients with less serious bacterial infections.
While a press release is a step in the right direction, Dear Doctor letters were still not issued. The Quinolone Vigilance Foundation feels that the labeling changes need to reach all prescribing physicians in the form of Dear Doctor letters.
We decided to take matters into our own hands. We wrote our own Dear Doctor letters and we launched a campaign to have them sent to every prescribing physician.
This is a massive and expensive undertaking, and to accomplish our mission, we need your help.
Please consider a donation to help us with printing and mailing costs. Any amount helps. QVF is a 501(c)(3) organization and you will receive a receipt for tax purposes.
- Mobile app info here
- PayPal: email@example.com
Check or money order to:
Quinolone Vigilance Foundation
PO Box 42527
Charlotte, NC 28215
After QVF launched the Dear Doctor letter campaign and began sending letters, Bayer, in a surprising move, sent out Dear Doctor letters regarding Avelox (moxifloxacin) and Cipro (ciprofloxacin). To date, Johnson and Johnson has not issued one.